Trial Profile
Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Tenofovir To Abacavir In HIV-1-Infected Subjects With Loss Of Bone Mineral Density
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Dec 2021
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Antiretrovirals; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; HIV protease inhibitors; Lamivudine; Non-nucleoside reverse transcriptase inhibitors; Raltegravir; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms OsteoTDF; OSTEOTENOFOVIR
- 06 Mar 2013 Interim results (n=48) presented at the 20th Conference on Retroviruses and Opportunistic Infections.
- 03 Oct 2011 Planned End Date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov
- 03 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov